Business Description
Esperion Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US29664W1053
Description
Financial Strength
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.31 | |||||
Equity-to-Asset | -2.21 | |||||
Debt-to-Equity | -0.59 | |||||
Debt-to-EBITDA | -1.77 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -11.76 | |||||
Beneish M-Score | -3 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -48.5 | |||||
3-Year EBITDA Growth Rate | 30.7 | |||||
3-Year EPS without NRI Growth Rate | 27.1 | |||||
3-Year FCF Growth Rate | 28.4 | |||||
3-Year Book Growth Rate | -1.2 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 48.76 | |||||
9-Day RSI | 43.56 | |||||
14-Day RSI | 43.44 | |||||
6-1 Month Momentum % | 240.34 | |||||
12-1 Month Momentum % | 135.92 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.29 | |||||
Quick Ratio | 0.87 | |||||
Cash Ratio | 0.53 | |||||
Days Inventory | 400.35 | |||||
Days Sales Outstanding | 126.79 | |||||
Days Payable | 206.84 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -65.8 | |||||
Shareholder Yield % | -14.93 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 62.81 | |||||
Operating Margin % | -133.72 | |||||
Net Margin % | -179.87 | |||||
FCF Margin % | -116.47 | |||||
ROA % | -90.08 | |||||
ROIC % | -581.89 | |||||
ROC (Joel Greenblatt) % | -6010.88 | |||||
ROCE % | -131.22 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1.87 | |||||
EV-to-EBIT | -3.73 | |||||
EV-to-Forward-EBIT | -6.2 | |||||
EV-to-EBITDA | -3.73 | |||||
EV-to-Forward-EBITDA | -6.2 | |||||
EV-to-Revenue | 4.82 | |||||
EV-to-Forward-Revenue | 2.1 | |||||
EV-to-FCF | -4.34 | |||||
Earnings Yield (Greenblatt) % | -26.78 | |||||
FCF Yield % | -35.93 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Esperion Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 107.925 | ||
EPS (TTM) (€) | -1.968 | ||
Beta | 2.07 | ||
Volatility % | 165.68 | ||
14-Day RSI | 43.44 | ||
14-Day ATR (€) | 0.161213 | ||
20-Day SMA (€) | 2.16805 | ||
12-1 Month Momentum % | 135.92 | ||
52-Week Range (€) | 0.666 - 2.988 | ||
Shares Outstanding (Mil) | 189.4 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Esperion Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Esperion Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Esperion Therapeutics Inc Frequently Asked Questions
What is Esperion Therapeutics Inc(FRA:0ET)'s stock price today?
When is next earnings date of Esperion Therapeutics Inc(FRA:0ET)?
Does Esperion Therapeutics Inc(FRA:0ET) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |